Current oncology最新文献

{"title":"Prognostic Factors and Treatment Outcomes in Gallbladder Cancer Patients Undergoing Curative Surgery: A Multicenter Retrospective Cohort Study.","authors":"Bowen Xu, Yanjiang Yin, Jianping Chang, Zhiyu Li, Xinyu Bi, Jianqiang Cai, Xiao Chen","doi":"10.3390/curroncol32060328","DOIUrl":"10.3390/curroncol32060328","url":null,"abstract":"<p><strong>Background: </strong>Gallbladder cancer (GBC) is a highly aggressive malignancy often diagnosed at an advanced stage due to its asymptomatic onset. Despite surgery being the only potentially curative option, recurrence and poor prognosis remain common, especially in advanced-stage diseases. There is limited consensus regarding the extent of lymphadenectomy, hepatic resection, and the role of adjuvant therapies. Identifying prognostic factors and optimizing treatment strategies are critical for improving outcomes. This multicenter retrospective study was conducted to evaluate the clinical and pathological predictors of survival and recurrence in GBC patients that underwent radical surgery and to assess the potential benefit of adjuvant therapies in advanced stages.</p><p><strong>Methods: </strong>This was a retrospective cohort study of GBC patients who underwent curative-intent resection for GBC between 2010 and 2022 at two tertiary medical centers in China. The baseline characteristics, surgical data, pathology, adjuvant therapy, and follow-up outcomes were analyzed. The survival outcomes were assessed using Kaplan-Meier methods and Cox regression models. Subgroup analyses were conducted to explore the impact of postoperative adjuvant chemotherapy, period of surgical treatment, and extent of resection. Multiple imputation was used to address missing data.</p><p><strong>Results: </strong>The 5-year overall survival (OS) rate was 57.4%. Independent predictors of a poorer OS included CA19-9 > 30 U/mL (HR = 1.861, <i>p</i> = 0.003), poor/moderate-to-poor differentiation (HR = 2.134, <i>p</i> = 0.004), T3-T4 stage (HR = 2.685, <i>p</i> = 0.001), N1-N2 stage (HR = 2.217, <i>p</i> = 0.002), M1 stage (HR = 2.308, <i>p</i> = 0.001), and a high CAN score (HR = 1.875, <i>p</i> = 0.009). Adjuvant chemotherapy improved the OS in the stage III-IV patients (24.8 vs. 17.3 months, <i>p</i> = 0.036), though the DFS improvement was not significant (<i>p</i> = 0.133). No survival difference was observed between the segment IVb + V resection and wedge resection in the T2b patients. The patients treated after 2017 had a better OS (<i>p</i> = 0.024), possibly due to improved surgical techniques and perioperative care.</p><p><strong>Conclusions: </strong>Radical surgery remains critical for GBC. Accurate staging and tailored perioperative strategies, including chemotherapy, may improve outcomes, though further prospective studies are needed to validate these findings.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12192010/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Voices from the Margins: Barriers and Facilitators to HPV Self-Sampling Among Structurally Marginalized People with a Cervix in the Greater Toronto Area and Ontario.","authors":"Mandana Vahabi, Natasha Kithulegoda, Masoomeh Moosapoor, Aisha Lofters, Josephine Pui-Hing Wong, Abdolreza Akbarian, Jenna Hynes","doi":"10.3390/curroncol32060327","DOIUrl":"10.3390/curroncol32060327","url":null,"abstract":"<p><p>Sex workers and formerly incarcerated people with a cervix face significant structural, interpersonal, and emotional barriers to cervical cancer screening, despite being at elevated risk for HPV infection. HPV self-sampling (HPV-SS) is a validated, user-directed method that has the potential to address these barriers, yet it remains excluded from Ontario's organized screening program. This qualitative study explored the lived experiences of structurally marginalized individuals with a cervix who were offered HPV-SS as part of a mixed-methods pilot in the Greater Toronto Area. Five virtual focus groups were conducted with 34 participants, including both those who used the HPV-SS kit and those who declined it. Using inductive thematic analysis, we identified barriers to traditional screening including fear, stigma, mistrust of healthcare providers, logistical constraints, and a lack of accessible information. HPV-SS was widely described as more acceptable, empowering, and emotionally manageable, offering participants autonomy, privacy, and control over their care. Concerns included swab design, uncertainty about correct use, and unclear follow-up after positive results. Participants offered concrete, community-informed recommendations to improve HPV-SS implementation, including opt-in distribution models, gender-affirming language, and trauma-informed educational materials. The findings highlight the urgent need to integrate HPV-SS into organized screening programs to advance equitable access to cervical cancer prevention for marginalized populations.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12192308/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perivascular Epithelioid Cell Tumor (PEComa) of the Sigmoid Colon: Case Report and Literature Review.","authors":"Gintare Slice, Rokas Stulpinas, Tomas Poskus, Marius Kryzauskas","doi":"10.3390/curroncol32060330","DOIUrl":"10.3390/curroncol32060330","url":null,"abstract":"<p><p>Perivascular epithelioid cell tumors (PEComas) are rare mesenchymal neoplasms characterized by perivascular epithelioid cell proliferation. They can occur in various organs, but colonic PEComas are exceptionally rare, showing diagnostic challenges due to their nonspecific clinical presentation and similar features to those of other colorectal tumors. We present a case of a 61-year-old female with defecation accompanied by blood clots, initially diagnosed with a suspected tumor in the sigmoid colon. Despite initial biopsy yielding non-informative material, repeat colonoscopy and imaging studies revealed a malignant tumor with multinucleated giant (osteoclast-like) cells and probable p53 mutation, most likely of mesenchymal origin. Robotic surgical resection was performed, and ultimately pathological examination refined the diagnosis as a malignant PEComa of the colon. This case demonstrates the importance of considering PEComa in the differential diagnosis of colonic tumors. Further research is needed to ascertain the clinical behavior and optimal treatment for colonic PEComas.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191435/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanisms and Functions of γδ T Cells in Tumor Cell Recognition.","authors":"Jing Tang, Chen Wu, Jintong Na, Yamin Deng, Simin Qin, Liping Zhong, Yongxiang Zhao","doi":"10.3390/curroncol32060329","DOIUrl":"10.3390/curroncol32060329","url":null,"abstract":"<p><p>γδ T cells are among the first line of defense in the immune system, playing a crucial role in bridging innate and adaptive immunity. Although γδ T cells are crucial for tumor immune surveillance, the complete mechanism by which γδ T cell receptors identify molecular targets in target cells remains unknown. Target cells can produce phosphoantigens (PAgs) via the mevalonate pathway or the methylerythritol phosphate pathway. The BTN3A1-BTN2A1 complex undergoes conformational changes in its extracellular domains upon binding to PAgs, leading to Vγ9Vδ2 T cell recognition. However, the structural basis of how Vγ9Vδ2 T cells recognize changes in this complex remains elusive. This review provides a detailed overview of the historical progress and recent discoveries regarding how Vγ9Vδ2 T cells recognize and target tumor cells. We also discuss the potential of γδ T cells immunotherapy and their role as antitumor agents.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12192272/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Self-Management Support for Cancer Survivors: A Descriptive Evaluation of the Symptom Navi Training from the Perspective of Health Care Professionals.","authors":"Marika Bana, Selma Riedo, Karin Ribi","doi":"10.3390/curroncol32060326","DOIUrl":"10.3390/curroncol32060326","url":null,"abstract":"<p><p>The Symptom Navi Program (SNP) is a self-management support (SMS) intervention for people with cancer. It consists of self-management supportive leaflets, educational conversations, and two standardized training sessions. A descriptive quality evaluation method was used to evaluate SNP implementation across 14 cancer services from 2021 to 2024. We evaluated training content, methods, and participants' confidence to use SMS in their clinical routine. Nurses, social workers, and psychologists completed ad hoc closed and open-ended questions after each training. The Work Sense of Coherence (Work-SoC) scale was used to elicit participants' self-reported perceptions of their work context at cancer services. A series of descriptive analyses were conducted on the Work-SoC scale, the training content, and the methods. In addition, training-specific questions and predefined hypotheses were correlated. Thematic analysis was employed to examine open-ended questions. The SNP training content and methods largely met participants' needs. Participants' confidence in applying educational conversations decreased over time. The findings suggest a robust correlation between the application of educational conversations in daily routines and the participants' perceptions regarding the comprehensibility and manageability of their work situations. Future research focusing on the implementation of SMS in clinical practice should examine the work context.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191559/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and Risk Factors of Platinum-Based Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Meta-Analysis.","authors":"Kaili Jin, Xianlei Lin, Xiaoting Xia, Huiling Ye, Dan Yang, Ying Fan, Qiuhua Sun, Rongyun Wang","doi":"10.3390/curroncol32060325","DOIUrl":"10.3390/curroncol32060325","url":null,"abstract":"<p><strong>Background: </strong>Platinum-based chemotherapy significantly increases the risk of nausea and vomiting, which can impair the treatment's efficacy and the patient's quality of life. This meta-analysis examines the incidence and risk factors of platinum-based chemotherapy-induced nausea and vomiting (PINV) in patients treated with this chemotherapy.</p><p><strong>Methods: </strong>This systematic review and meta-analysis were conducted in accordance with the PRISMA 2020 guidelines. We conducted a literature search in the databases PubMed, Embase, Web of Science, WanFang, China Science and Technology Journal Database (VIP), China National Knowledge Infrastructure (CNKI), and Chinese Medical Association Journal Database (CMAJD) through to 20 January 2025. Studies that reported the incidence and identified risk factors of nausea and vomiting specifically in patients receiving platinum-based chemotherapy were included in the review. The data were extracted independently by two reviewers. The odds ratios (ORs) for each risk factor were calculated from the included studies. Sensitivity analyses and additional subgroup analyses were performed to ensure the robustness of our findings.</p><p><strong>Results: </strong>This meta-analysis included 32 studies involving 14,207 participants. Female sex (OR = 2.363, 95% CI = 1.363-4.096, <i>p</i> = 0.002), anxiety (OR = 1.689, 95% CI = 1.057-2.700, <i>p</i> = 0.028), fatigue (OR = 1.413, 95% CI = 1.145-1.744, <i>p</i> = 0.001), motion sickness (OR = 1.816, 95% CI = 1.266-2.605, <i>p</i> = 0.001), and a history of vomiting during chemotherapy (OR = 2.728, 95% CI = 1.468-5.069, <i>p</i> = 0.002) were significantly associated with an increased risk of PINV.</p><p><strong>Conclusion: </strong>Female sex, anxiety, fatigue, motion sickness, and a history of vomiting during chemotherapy increase the risk of PINV during platinum-based treatments.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191659/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Incidence Trend of Early-Onset Obesity-Related and Non-Obesity-Related Cancers.","authors":"Miyu Terashima, Kota Nakayama, Satoko Ugai, Hwa-Young Lee, Yuta Tsukumo, Etsuji Suzuki, Hiroki Mizuno, Minkyo Song, Naoko Sasamoto, Ichiro Kawachi, Tomotaka Ugai","doi":"10.3390/curroncol32060324","DOIUrl":"10.3390/curroncol32060324","url":null,"abstract":"<p><p>The global rise in obesity prevalence and the incidence of early-onset cancer (diagnosed between 20 and 49 years of age) is a serious public health concern. We, therefore, evaluated the recent global trends in the incidence of early-onset obesity-related cancers and compared them to those of non-obesity-related cancers. We obtained age-standardized incidence rates of early-onset cancers diagnosed between 2000 and 2012 in 44 countries from the Cancer Incidence in Five Continents database. Using joinpoint regression models, we calculated the average annual percentage changes (AAPCs) and their corresponding 95% confidence intervals (95% CIs) for combined and individual categories of obesity-related cancers (11 and 9 cancer types in females and males, respectively) and non-obesity-related cancers (12 cancer types in both females and males). Differences in the AAPC were assessed by comparing 95% CIs, where nonoverlapping 95% CIs were considered statistically significantly different. We observed statistically significant positive AAPCs for early-onset obesity-related cancers in all available countries combined among females (global AAPC, 4.3%; 95% CI, 4.1-4.6%) and males (global AAPC, 1.4%; 95% CI, 1.2-1.7%). When analyzed by countries, we observed statistically significant positive AAPCs in 26 countries among females and 11 countries among males. AAPCs for early-onset obesity-related cancers were statistically significantly higher than those of non-obesity-related cancers in several regions, especially North America and Oceania. In conclusion, this study indicates that the incidence of early-onset obesity-related cancers exhibited a more pronounced increasing trend than non-obesity-related cancers among both sexes in many countries and regions.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191960/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Clinical-Radiomics Nomogram for the Preoperative Prediction of Aggressive Micropapillary and a Solid Pattern in Lung Adenocarcinoma.","authors":"Xiangyu Xie, Lei Chen, Kun Li, Liang Shi, Lei Zhang, Liang Zheng","doi":"10.3390/curroncol32060323","DOIUrl":"10.3390/curroncol32060323","url":null,"abstract":"<p><p><b>Background:</b> A micropapillary pattern (MP) and solid pattern (SP) in lung adenocarcinoma (LUAD), a major subtype of non-small-cell lung cancer (NSCLC), are associated with a poor prognosis and necessitate accurate preoperative identification. This study aimed to develop and validate a predictive model combining clinical and radiomics features for differentiating a high-risk MP/SP in LUAD. <b>Methods:</b> This retrospective study analyzed 180 surgically confirmed NSCLC patients (Stages I-IIIA), randomly divided into training (70%, n = 126) and validation (30%, n = 54) cohorts. Three prediction models were constructed: (1) a clinical model based on independent clinical and CT morphological features (e.g., nodule size, lobulation, spiculation, pleural indentation, and vascular abnormalities), (2) a radiomics model utilizing LASSO-selected features extracted using 3D Slicer, and (3) a comprehensive model integrating both clinical and radiomics data. <b>Results:</b> The clinical model yielded AUCs of 0.7975 (training) and 0.8462 (validation). The radiomics model showed superior performance with AUCs of 0.8896 and 0.8901, respectively. The comprehensive model achieved the highest diagnostic accuracy, with training and validation AUCs of 0.9186 and 0.9396, respectively (DeLong test, <i>p</i> < 0.05). Decision curve analysis demonstrated the enhanced clinical utility of the combined approach. <b>Conclusions:</b> Integrating clinical and radiomics features significantly improves the preoperative identification of aggressive NSCLC patterns. The comprehensive model offers a promising tool for guiding surgical and adjuvant therapy decisions.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12192257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Necessity and Reconstruction Methods of Splenic Vein After Resection of the Portomesenteric Junction During Resections for Pancreatic Cancer.","authors":"Moath Alarabiyat, Nikolaos Chatzizacharias","doi":"10.3390/curroncol32060316","DOIUrl":"10.3390/curroncol32060316","url":null,"abstract":"<p><p>Pancreatic cancer involving the porto-mesenteric junction (PMJ) represents a challenge to pancreatic surgeons. Restoring mesenteric venous drainage is an essential component of vascular reconstruction after tumour resection. In contrast, management of the splenic venous drainage can involve the ligation or reconstruction of the splenic vein (SV). Evidence suggests that splenic vein ligation (SVL) is commonly associated with sinistral portal hypertension (SPH), especially if multiple venous tributaries were divided to facilitate resection. Although the association between SVL and SPH is well documented, the risk of symptomatic SPH is not widely reported, presumably due to the low incidence and poor survival of pancreatic cancer patients. Splenic vein reconstruction (SVR) has been proposed to decrease the risk of SPH but is fraught with technical complexity and increased morbidity. Moreover, SVR does not guarantee the prevention of SPH, as patency rates vary and associated hemodynamic changes are unpredictable. Patient selection and the surgical expertise available can guide SV intraoperative management, taking into consideration the risks and benefits associated with each approach. A comprehensive review of the current literature highlighting the incidence and clinical impact of SPH after the resection of pancreatic cancer involving the PMJ is presented.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12192409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Design of a Patient-Centered Hierarchal Composite Outcome for a Multi-Center Randomized Controlled Trial in Metastatic Bone Disease.","authors":"Hadia Farrukh, Abbey Kunzli, Olivia Virag, Nathan O'Hara, Sheila Sprague, Amy Cizik, Ricardo Gehrke-Becker, Thomas Schubert, Michelle Ghert","doi":"10.3390/curroncol32060318","DOIUrl":"10.3390/curroncol32060318","url":null,"abstract":"<p><p>The proximal femur represents the most frequent site in the appendicular skeleton for metastatic bone disease (MBD) to occur, with a high risk for pathologic fracture. While surgical stabilization is typically used to manage fractures, reconstruction approaches are gaining popularity due to improved survival. Previous studies have focused on clinical outcomes, but patient-centered outcomes remain underexplored. This study aims to develop a patient-centered primary outcome for the Proximal FEmur Reconstruction or Internal Fixation fOR Metastases (PERFORM) Randomized Controlled Trial, employing a mixed-methods approach. First, a focus group with advanced cancer patients and caregivers identified relevant outcomes. Next, a discrete choice experiment (DCE) assessed the importance of these outcomes among stakeholders, including surgeons, patients and caregivers. The most important components for the primary outcome were identified: mortality within twelve months, physical function assessed at four months using the PROMIS^® Global Physical Function score, and the number of days at home within twelve months. The DCE further confirmed that survival and physical function were most prioritized. The PERFORM trial's primary outcome, developed through extensive stakeholder engagement, will guide the evaluation of surgical approaches for MBD of the proximal femur and has the potential to influence patient-centered practice.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191994/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}